de Wit R, Schattenkerk J K, Boucher C A, Bakker P J, Veenhof K H, Danner S A
Department of Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Lancet. 1988 Nov 26;2(8622):1214-7. doi: 10.1016/s0140-6736(88)90810-0.
The effectiveness and antiretroviral activities of interferon-alpha in AIDS-related Kaposi's sarcoma was assessed in a non-randomised, phase-II clinical trial. 28 patients were treated with high-dose (27-36 MU) human recombinant interferon-alpha 2a subcutaneously every day for 8 weeks. In patients with stable disease or showing a response, treatment was continued three times weekly until a complete response was achieved or there was progression. 12 of the 26 evaluable patients achieved a major response; 5 of these showed histologically confirmed complete responses. There was a significant increase in OKT4-positive cells in the responders and a significant decrease in HIV antigen (HIV-Ag) in the 7 responders with initially detectable HIV-Ag. Interferon-alpha is thus an effective treatment. The increase in OKT4-positive cells and the decrease in HIV-Ag seem to be significantly related to patients with tumour responses.
在一项非随机的II期临床试验中评估了α干扰素对艾滋病相关卡波西肉瘤的有效性和抗逆转录病毒活性。28例患者每天皮下注射高剂量（27 - 36MU）人重组α干扰素2a，持续8周。对于病情稳定或有反应的患者，继续每周三次治疗，直至达到完全缓解或病情进展。26例可评估患者中有12例获得主要反应；其中5例经组织学证实为完全缓解。反应者中OKT4阳性细胞显著增加，7例初始可检测到HIV抗原（HIV-Ag）的反应者中HIV-Ag显著减少。因此，α干扰素是一种有效的治疗方法。OKT4阳性细胞的增加和HIV-Ag的减少似乎与肿瘤反应患者显著相关。
